Advancing HS Care - An Interactive Learning Experience

Hidradenitis suppurativa (HS) remains a complex, painful chronic inflammatory condition with significant unmet needs in real-world practice. Recent clinical evidence is reshaping how dermatologists think about targeted biologic therapy in this space, and Secukinumab is at the forefront of that evolution. This Innovation Experience brings together two pivotal clinical posters and expert video insights to highlight important Secukinumab data and translate it into practical takeaways you can use in your clinic.

Evolving CSU Management - An Interactive Learning Experience

Chronic Spontaneous Urticaria (CSU) can be unpredictable, persistent, and frustrating for patients and clinicians alike. Emerging data on remibrutinib, a next-generation oral BTK inhibitor, offers promising insights into targeted control of CSU symptoms including improvements in itch and overall disease burden. This Innovation Experience brings together two key clinical posters and expert video insights to help you quickly interpret the evidence and translate it into real-world treatment considerations.

Atopic Dermatitis: Treating Beyond What You See

For many clinicians, escalation in AD isn’t tied to a single threshold anymore. It’s a judgment call, shaped by what the disease is doing over time and how much it’s affecting the patient’s day-to-day life. As familiarity with biologics has grown, along with reassuring safety data and broader indications, there’s been a noticeable shift toward earlier use, particularly with therapies targeting type 2 inflammation. This portion of the Biologics Innovation Experience examines how that shift is playing out in practice and the ways it’s changing when and how we intervene.

Rethinking Psoriatic Disease

Treating psoriatic disease means paying attention to what’s visible on the skin and what may be unfolding beneath it. With the expansion of deucravacitinib into psoriatic arthritis, the question is no longer just which therapy improves plaques. It’s how we identify patients earlier, think about joint risk in a dermatology setting, and make decisions for patients who don’t quite fit our usual categories. Across the experience, faculty translate this into practice by exploring how often psoriatic arthritis is missed or delayed, which patients begin to stand out, where an oral TYK2 inhibitor may fit, and what remains unresolved in day-to-day care.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data

Pooled Phase 3 Data From CSU Trials

CSU Disease Activity Data From a Phase 3 Trial